10 documents found, page 1 of 1

Sort by Issue Date

Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression...

Macedo, Danielle; Chaves Filho, Adriano José Maia; Sousa, Caren Nádia Soares de; Quevedo, João; Barichello, Tatiana; Nobre Júnior, Hélio Vitoriano

Objectives The first drug repurposed for the treatment of depression was the tuberculostatic iproniazid. At present, drugs belonging to new classes of antidepressants still have antimicrobial effects. Dysbiosis of gut microbiota was implicated in the development or exacerbation of mental disorders, such as major depressive disorder (MDD). Based on the current interest in the gut-brain axis, the focus of this na...

Date: 2018   |   Origin: Oasisbr

α-Lipoic acid as adjunctive treatment for schizophrenia : an open-label trial

Sanders, Lia Lira Olivier; Menezes, Carlos Eduardo de Souza; Chaves Filho, Adriano José Maia; Viana, Glautemberg de Almeida; Fechine, Francisco Vagnaldo

Purpose/Background: Accumulating evidence suggests an involvement of oxidative stress in the pathophysiology of schizophrenia. This offers a hypothesis-derived therapeutic approach to hinder oxidative damage and its clinical sequelae. α-Lipoic acid (ALA) is a powerful natural antioxidant indicated to treat diabetic neuropathy. Methods/Procedures: In this pilot investigation, we administered ALA (100 mg/d) for 4...

Date: 2018   |   Origin: Oasisbr

IDO chronic immune activation and tryptophan metabolic pathway : a potential pa...

Chaves Filho, Adriano José Maia; Lima, Camila Nayane Carvalho; Vasconcelos, Silvânia Maria Mendes; Lucena, David Freitas de; Maes, Michael

Obesity and depression are among the most pressing health problems in the contemporary world. Obesity and depression share a bidirectional relationship, whereby each condition increases the risk of the other. By in- ference, shared pathways may underpin the comorbidity between obesity and depression. Activation of cell- mediated immunity (CMI) is a key factor in the pathophysiology of depression. CMI cytokines,...

Date: 2017   |   Origin: Oasisbr

Neonatal Immune Challenge with Lipopolysaccharide Triggers Long-lasting sex- an...

Custódio, Charllyany Sabino; Mello, Bruna Stefânia Ferreira; Chaves Filho, Adriano José Maia; Lima, Camila Nayane de Carvalho

Early-life challenges, particularly infections and stress, are related to neuropsychiatric disorders such as autism and schizophrenia. Here, we conducted a wide range of behavioral tests in periadolescent (postnatal day (PN) 35) and adult (PN70) Swiss mice neonatally challenged with LPS on PN5 and -7, to unveil behavioral alterations triggered by LPS exposure. Immune and neurotrophic (brain-derived neurotrophic...

Date: 2017   |   Origin: Oasisbr

N-acetylcysteine attenuates nicotine-induced kindling in female periadolescent ...

Okamura, Adriana Mary Nunes Costa; Gomes, Patrícia Xavier L.; Oliveira, Gersilene V. de; Araújo, Fernanda Yvelize R. de; Tomaz, Viviane S.

Kindling We recently demonstrated that female periadolescent rats are more vulnerable to nicotine (NIC)-induced kindling than their male counterparts. Furthermore, we evidenced that decreases in brain antioxidative defenses may contribute to this gender difference. Here we aimed to determine the preventive effects of the antioxidant N-acetyl cysteine (NAC) against NIC-kindling in female periadolescent rats. To ...

Date: 2016   |   Origin: Oasisbr

Preclinical evidences for an antimanic effect of carvedilol

Souza, Greicy Coelho de; Gomes, Julia Ariana de S.; Queiroz, Ana Isabelle de Góis; Araújo, Maíra Morais de; Cavalcante, Lígia Menezes

Oxidative imbalance, alterations in brain-derived neurotrophic factor (BDNF), and mitochondrial dysfunction are implicated in bipolar disorder (BD) pathophysiology and comorbidities, for example, cardiovascular conditions. Carvedilol (CVD), a nonselective beta-blocker widely used for the treatment of hypertension, presents antioxidant and mitochondrial stabilizing properties. Thus, we hypothesized that CVD woul...

Date: 2016   |   Origin: Oasisbr

Prevention and reversal of ketamine-induced schizophrenia related behavior by m...

Monte, Aline Santos; Souza, Greicy Coelho de; McIntyre, Roger S.; Soczynska, Joanna K.; Santos, Júnia Vieira dos; Cordeiro, Rafaela Carneiro

It has been hypothesized that oxidative imbalance and alterations in nitrergic signaling play a role in the neurobiology of schizophrenia. Preliminary evidence suggests that adjunctive minocycline treatment is efficacious for cognitive and negative symptoms of schizophrenia. This study investigated the effects of minocycline in the prevention and reversal of ketamine-induced schizophrenia-like behaviors in mice...

Date: 2014   |   Origin: Oasisbr

Angiotensin receptor blockers for bipolar disorder

Queiroz, Ana Isabelle de Góis; Medeiros, Camila Dantas; Ribeiro, Bruna Mara Machado; Lucena, David Freitas de; Macêdo, Danielle Silveira

Studies have suggested that the brain renin angiotensin system (RAS) regulates cerebral flow, autonomic and hormonal systems, stress, innate immune response and behavior, being implicated in several brain disorders such as major depression, Parkinson’s and Alzheimer’s disease. The angiotensin II receptor sub- type 1 (AT1R) is distributed in brain regions responsible for the control of stress response through pe...

Date: 2013   |   Origin: Oasisbr

O uso da amantadina na esquizofrenia

Lucena, David Freitas de

Novos tratamentos para a esquizofrenia são desejados devido a baixa resposta terapeutica dos fármacos atuais. Através de revisão sistemática da literatura e estudos anteriores realizados pelo Programa de Demências e Esquizofrenias da UFRGS, os adamantanos (memantina e amantadina), vêm mostrando-se como moléculas promissoras principalmente para pacientes refratários aos uso convencional de neurolépticos. Inicial...

Date: 2012   |   Origin: Oasisbr

Ensaio clínico randomizado, duplo-cego, controlado por placebo, para avaliar o ...

Lucena, David Freitas de

A desregulação glutamatérgica parece ter uma importante participação na neurofisiopatologia da esquizofrenia, principalmente através da disfunção do receptor NMDA. A Memantina, uma droga aprovada pelo FDA para o tratamento da doença de Alzheimer de grau moderado a severo age como um antagonista fraco e não seletivo dos receptores NMDA. O objetivo deste estudo é examinar a eficácia da memantina como tratamento a...

Date: 2010   |   Origin: Oasisbr

10 Results

Queried text

Refine Results

Author





















Date








Document Type




Access rights


Resource


Subject